Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 August 2020 | Story Nitha Ramnath | Photo Supplied

A VUCA environment reflects a state of the external world, or external to the leader, community, or nation, as much as it seems to reflect an internal frame of mind. The constant pressure to lead, while being uncertain about the outcomes of your decisions and even fearful of not being in control all the time, are some of the hallmarks of a VUCA world. A good way of thinking about this concept is to view it as the ‘new narrative’ – the volatility, uncertainty, complexity, and ambiguity inherent in today’s world.

Leaders in the 21st century need to steer a country securely through unparalleled, challenging, and stormy circumstances such as food insecurity, political unrest, migration and refugee issues, unemployment, divided societies and prejudice, global warming, and others. Against this introduction, it unfortunately appears as if there is an increase in VUCA problems in the 21st century, and leaders often fail in their attempts to provide solutions to these demanding circumstances. Indeed, it appears as if leaders in the 21st century are actually contributing to VUCA environments. So-called ‘state capture’ and the ‘gangster state’ in South Africa, ‘make America great again’ and ‘America first’ , the Brexit no-deal option, ‘trade wars’, and ‘the deadly coronavirus’ are examples of when leaders did not appear to solve challenges, but rather to intensify them. 

This is the backdrop against which the book, Chaos is a Gift? Leading Oneself in Uncertain and Complex Environments, has been conceptualised – indeed to debate the opportunities that exist amid this chaos. 

Three UFS women academics contributed to this book.

Dr Martha Harunavamwe (Department of Industrial Psychology) has written a chapter on resilience and agility in Zimbabwean higher education.Dr Mareve Biljohn (Department of Public Administration and Management) has written a chapter on leading the self in South Africa’s VUCA local government environments. Prof Liezel Lues (Department of Public Administration and Management) has written a chapter on South Africa’s surviving VUCA environment. She is also one of the editors of the book.

The endorsement written by Prof Petersen, reads: There are various books on leadership, but this book, in navigating today’s volatile, uncertain, complex and ambiguous (VUCA) environment, presents chaos as both an opportunity and possibility in developing ‘selfcare practices’ in leading oneself. Leaders must have the cognitive flexibility to adapt to the unknown in the midst of chaos (and a crisis). Through making sense of leadership approaches in different environments, including the business, private, academic and public sectors, as well as in conflict/post-conflict situations, the book provides a deep insight into leading oneself effectively with innovation and empathy in a VUCA environment – an excellent contribution to self-leadership. (Francis Petersen, Rector and Vice-Chancellor: Top Management, University of the Free State)

The book, published by KR Publishers, will be launched on 27 August 2020. Prof Ebben van Zyl, together with Prof Lues, are the editors of this book: Van Zyl, E, Campbell, A and Lues, L. ed. Chaos is a Gift? Leading Oneself in Uncertain and Complex Environments. Randburg: KR Publishing. ISBN: 978-1-86922-860-6

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept